Unknown

Dataset Information

0

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.


ABSTRACT: BACKGROUND:Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare hereditary kidney cancer syndrome in which affected individuals are at risk of skin and uterine leiomyomatosis and kidney cancer. HLRCC-associated kidney cancer is a lethal disease with a highly aggressive behavior, and there is no standard treatment option for metastatic disease. CASE PRESENTATION:Here, we report a 29-year-old patient with a locally advanced HLRCC-assiciated RCC. He was administrated temsirolimus initially, then underwent surgical removal of kidney, retroperitoneal lymph nodes, inferior vena cava and tumor thrombi. Unfortunately, multiple liver metastases were confirmed 1 month after surgery, so axitinib was given but failed immediately. We tried bevacizumab plus erlotinib, which achieved long-term good response lasting more than 18?months. He is alive with disease and maintains bevacizumab plus erlotinib treatment. CONCLUSION:The promising results obtained in this patient suggest that combined bevacizumab plus erlotinib may offer a valid treatment option for advanced HLRCC-associated kidney cancer, even after failures of mTOR inhibitor and/or VEGFR TKI based therapies.

SUBMITTER: Park I 

PROVIDER: S-EPMC6558845 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.

Park Inkeun I   Shim Young Sup YS   Go Heounjeong H   Hong Bum Sik BS   Lee Jae Lyun JL  

BMC urology 20190610 1


<h4>Background</h4>Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare hereditary kidney cancer syndrome in which affected individuals are at risk of skin and uterine leiomyomatosis and kidney cancer. HLRCC-associated kidney cancer is a lethal disease with a highly aggressive behavior, and there is no standard treatment option for metastatic disease.<h4>Case presentation</h4>Here, we report a 29-year-old patient with a locally advanced HLRCC-assiciated RCC. He was administrated  ...[more]

Similar Datasets

| S-EPMC6790829 | biostudies-literature
| S-EPMC4074185 | biostudies-literature
| S-EPMC7814596 | biostudies-literature
| S-EPMC6279512 | biostudies-literature
| S-EPMC10404549 | biostudies-literature
| S-EPMC8554149 | biostudies-literature
| S-EPMC3873008 | biostudies-other
| S-EPMC4574691 | biostudies-literature
| S-EPMC4647878 | biostudies-literature